US Supreme Court Asked To Review Timing Of Biosimilar Entry

In Zarxio case, Sandoz petitions high court to determine whether notice of biosimilar commercial marketing can be given before FDA approval; court may await rulings in pending cases interpreting the biosimilars statute.